CN111566086A - 同时抑制lsd1和hdac靶点的化合物及其应用 - Google Patents

同时抑制lsd1和hdac靶点的化合物及其应用 Download PDF

Info

Publication number
CN111566086A
CN111566086A CN201880084945.2A CN201880084945A CN111566086A CN 111566086 A CN111566086 A CN 111566086A CN 201880084945 A CN201880084945 A CN 201880084945A CN 111566086 A CN111566086 A CN 111566086A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
compound
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880084945.2A
Other languages
English (en)
Other versions
CN111566086B (zh
Inventor
全军民
李勤凯
曾鑫
许正双
岳宏
张婷瑶
付佳苗
黄新仪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University Shenzhen Graduate School
Original Assignee
Peking University Shenzhen Graduate School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University Shenzhen Graduate School filed Critical Peking University Shenzhen Graduate School
Publication of CN111566086A publication Critical patent/CN111566086A/zh
Application granted granted Critical
Publication of CN111566086B publication Critical patent/CN111566086B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种化合物，所述化合物的结构通式如式I所示：X‑AB‑Y(式I)；上述式I中，X选自‑CO2H、‑CONHZ、‑CH＝CH‑CO2H、‑CH＝CH‑CONHZ中的任意一种，其中，Z选自被取代的或未被取代的C1‑C12烷基、被取代的或未被取代的芳基、羟基中的任意一种；Y＝‑NR1R2，其中，NR1R2为被取代的或未被取代的3元至9元的含氮杂环烃基；A、B分别独立选自取代的或未被取代的亚苯基、取代的或未被取代的氮杂亚苯基。该化合物或其相应的药用的盐的形式，可同时抑制LSD1和HDAC靶蛋白，从而抑制多种肿瘤细胞的增殖，具有很好的抗肿瘤作用。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201880084945.2A 2018-01-04 2018-01-04 同时抑制lsd1和hdac靶点的化合物及其应用 Active CN111566086B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/071317 WO2019134087A1 (zh) 2018-01-04 2018-01-04 同时抑制lsd1和hdac靶点的化合物及其应用

Publications (2)

Publication Number Publication Date
CN111566086A true CN111566086A (zh) 2020-08-21
CN111566086B CN111566086B (zh) 2023-08-01

Family

ID=67143594

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880084945.2A Active CN111566086B (zh) 2018-01-04 2018-01-04 同时抑制lsd1和hdac靶点的化合物及其应用

Country Status (5)

Country Link
US (1) US20200331882A1 (zh)
EP (1) EP3736266A4 (zh)
JP (1) JP2021510152A (zh)
CN (1) CN111566086B (zh)
WO (1) WO2019134087A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444069A (zh) * 2021-07-07 2021-09-28 新乡医学院 一类2-芳基-4-(1h-吡唑-3-基)吡啶类lsd1/hdac双靶点抑制剂

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
WO2023222115A1 (zh) * 2022-05-20 2023-11-23 四川汇宇制药股份有限公司 一种羟基酰胺类衍生物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801170A (en) * 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
CN1425026A (zh) * 2000-02-21 2003-06-18 藤泽药品工业株式会社 环六肽衍生物
CN101198586A (zh) * 2005-06-28 2008-06-11 希格马托制药工业公司 联苯基和萘基-苯基异羟肟酸衍生物
WO2008069619A1 (en) * 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
CN101405265A (zh) * 2006-01-31 2009-04-08 因塞特公司 酰氨基化合物及其作为药物的应用
WO2013180066A1 (ja) * 2012-05-28 2013-12-05 興和株式会社 Ｔｌｒ阻害作用を有するピリジン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0415367D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
AR050926A1 (es) * 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
FR2892412B1 (fr) * 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
CN105153007B (zh) * 2015-09-07 2017-10-27 北京理工大学 一种荧光点亮型检测爆炸物的荧光材料、制备方法及应用
BR112018067392A2 (pt) * 2016-03-01 2019-01-02 Propellon Therapeutics Inc inibidores de ligação entre proteínas wdr5
CN109153636B (zh) * 2016-05-09 2021-10-22 朱比连特埃皮科尔有限责任公司 作为双重lsd1/hdac抑制剂的环丙基-酰胺化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801170A (en) * 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
CN1425026A (zh) * 2000-02-21 2003-06-18 藤泽药品工业株式会社 环六肽衍生物
CN101198586A (zh) * 2005-06-28 2008-06-11 希格马托制药工业公司 联苯基和萘基-苯基异羟肟酸衍生物
CN101405265A (zh) * 2006-01-31 2009-04-08 因塞特公司 酰氨基化合物及其作为药物的应用
WO2008069619A1 (en) * 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
WO2013180066A1 (ja) * 2012-05-28 2013-12-05 興和株式会社 Ｔｌｒ阻害作用を有するピリジン誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARRY R. SMITH ET AL.: "Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: Extending towards the β-exosite", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
GUODONG LIANG ET AL.: "An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors", 《ORGANIC & BIOMOLECULAR CHEMISTRY》 *
YONG WANG ET AL.: "Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444069A (zh) * 2021-07-07 2021-09-28 新乡医学院 一类2-芳基-4-(1h-吡唑-3-基)吡啶类lsd1/hdac双靶点抑制剂

Also Published As

Publication number Publication date
WO2019134087A1 (zh) 2019-07-11
EP3736266A1 (en) 2020-11-11
JP2021510152A (ja) 2021-04-15
CN111566086B (zh) 2023-08-01
US20200331882A1 (en) 2020-10-22
EP3736266A4 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
CN107474011B (zh) 一类2-苯基-4-苯乙烯基吡啶类lsd1抑制剂、其制备方法及应用
US20200331882A1 (en) Compound for simultaneously inhibiting lsd1 and hdac targets and application thereof
CN104169260A (zh) 新三嗪衍生物
Zhan et al. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1, 2, 3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
Zhan et al. 1, 2, 3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation
Cui et al. Design, synthesis, bioactivity, and DFT calculation of 2-thiazolyl-hydrazone derivatives as influenza neuraminidase inhibitors
Mushtaque et al. Synthesis, Characterization, Molecular Docking, and Anticancer Evaluation of 4‐Thiazolidinone Analogues
Rinaldi et al. A versatile and practical synthesis toward the development of novel HIV‐1 integrase inhibitors
CN114685382A (zh) 具有HDACs抑制活性的喹唑啉-4-胺衍生物及其制备方法与用途
Han et al. Design, synthesis and preliminary bioactivity studies of 1, 2-dihydrobenzo [d] isothiazol-3-one-1, 1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors
Andrianov et al. Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR
CN109761898B (zh) 一种双靶点抑制剂及其制备方法和用途
CA2719074C (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
CN102010348A (zh) 水杨酰胺酯类衍生物、制备方法及其应用
EP3241823B1 (en) Pyrrole amide compound, preparation method therefor, and use thereof
CN103833540B (zh) 一种β-取代查尔酮类似物及其制备方法和在制备组蛋白去乙酰化酶抑制剂中的应用
CN112390781A (zh) 二芳基取代的1,1-乙烯类化合物、制备方法及用途
CN111646937A (zh) 一种 n-乙酰基环丙沙星的丙烯酮衍生物及其制备方法和应用
Sharma et al. Synthesis, antibacterial and anticancer activities of some novel imidazoles
CN110938055A (zh) 六元环甲酰胺类化合物及其合成方法和应用
CN110818719A (zh) 用于制备抗肿瘤药物的联二萘酚-朝格尔碱胺希夫碱衍生物的合成方法与应用
WO2022166990A1 (zh) 用于抗肿瘤的药物组合
Guzmán Ramírez et al. Synthesis of N‐aminophalimides derived from α‐amino acids: Theoretical study to find them as HDAC8 inhibitors by docking simulations and in vitro assays
WO2021092892A1 (zh) 喹啉或喹唑啉类化合物在制备抗肿瘤药物中的应用
CN115572254A (zh) 2,6-二芳基吡啶类HDAC/Tubulin双功能抑制剂及制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant